NewsBenzingaAmneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est Benzinga 2026.11.03 11:07 (GMT+0) Open on Benzinga Other news Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition Dear Nvidia Stock Fans, Mark Your Calendars for December 10 Nvidia clarifies when it will — and won’t —keep financing neoclouds Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease